After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
EXAS belongs to the Healthcare sector of the NASDAQ while operating in the Diagnostics & Research industry. The current market capitalization of Exact Sciences Corp is $12.54B. A total of 3.01 million shares were traded on the day, compared to an average of 3.05M shares.
In the most recent transaction, Herriott James sold 1,500 shares of EXAS for 70.08 per share on Nov 04 ’25. After the transaction, the SVP, General Counsel & Sec now owns 12,585 company shares. In a previous transaction on Nov 04 ’25, Baranick Brian sold 2,858 shares at 70.08 per share. EXAS shares that EVP, GM, Precision Oncology owns now total 22,368.
Among the insiders who bought shares, Baranick Brian acquired of 2,858 shares on Nov 04 ’25 at a per-share price of $70.08. In another insider transaction, Herriott James bought 1,500 shares at $70.08 per share on Nov 04 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, EXAS has a high of $72.81 and a low of $38.81.
As of this writing, EXAS has an earnings estimate of $0.17 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of $0.28 per share and a lower estimate of $0.01. The company reported an EPS of -$0.06 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. EXAS’s latest balance sheet shows that the firm has $1.03B in Cash & Short Term Investments as of fiscal 2021. There were $2.38B in debt and $517.07M in liabilities at the time. Its Book Value Per Share was $13.20, while its Total Shareholder’s Equity was $3.39B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EXAS is Buy with a score of 4.82.
